Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification
about
Causal models and learning from data: integrating causal modeling and statistical estimationImmune activation, CD4+ T cell counts, and viremia exhibit oscillatory patterns over time in patients with highly resistant HIV infectionLong-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensThe challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.Super Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring.Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test.Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimensA simulation study of finite-sample properties of marginal structural Cox proportional hazards models.The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death.Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study.Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcomeMean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings.Quantitatively monitoring AIDS policy implementation in China.Monitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling studyViral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa.Persistent difficulties in switching to second-line ART in sub-saharan Africa--a systematic review and meta-analysis.Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectivenessEarly outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa.Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trialCD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.HIV treatment and care in resource-constrained environments: challenges for the next decade.Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095.Evaluation of the Effect of a Continuous Treatment: A Machine Learning Approach with an Application to Treatment for Traumatic Brain Injury.Surveillance of HIV drug resistance in children receiving antiretroviral therapy: a pilot study of the World Health Organization's generic protocol in Maputo, Mozambique.Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy.Treatment switching in South Indian patients on HAART: what are the predictors and consequences?Evaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in IndiaImpact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China.AIDS and drug rationingDevelopment and validation of systems for rational use of viral load testing in adults receiving first-line ART in sub-Saharan AfricaViral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis.The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring.Pooled HIV-1 RNA viral load testing for detection of antiretroviral treatment failure in Kenyan children.First-line antiretroviral treatment failure and associated factors in HIV patients at the University of Gondar Teaching Hospital, Gondar, Northwest EthiopiaIncreasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.
P2860
Q26852777-5E3AE1EF-7BF5-42EB-B51D-878CF220AB15Q28478654-0547976B-1DAC-4BBC-96C9-040836292212Q28485321-7DF30738-A6BE-4557-B1F2-E95225654BA2Q30425595-DAE16D5D-C20A-4B99-BC3E-90A3A9465E5CQ30944694-585197DC-7DFE-41C3-874E-E971789EE369Q33574798-1EA8ADDF-3ABE-4589-A87B-069C9DD5CE52Q33984137-A3DF57AA-D82A-481E-97B3-1BB9929189E1Q34137798-9F72E1AC-27C2-40EA-A610-8A7118D62E4CQ34227946-1A92F54E-B132-4950-B374-B4A82E1B9BA0Q34229301-CFC5A46A-FFC9-4422-94A8-2E1421FDE376Q34289544-D652E763-8389-45B3-A403-336022AEF0C0Q34292437-7BFC6990-50CC-4C49-8368-355E3BADFC86Q34320076-79811294-6DEB-4593-BC2F-8EF9519E2155Q34354329-67D22B7C-438B-40F3-82B1-BA073808C27AQ34612284-615B0060-880B-48AB-BFE6-2E8AFE959153Q34683397-D01D5CD8-EE59-4D2E-864A-6B7867EA43EBQ35049762-8C478457-8892-4244-8995-D4F7C6918417Q35077695-7C224891-1F34-4430-84E4-89EBD66D9CECQ35217495-0CC0D023-E424-4F6A-AE83-401A6D49E9D7Q35575725-6EF02EEC-BA16-48C5-ADF4-530A0E48ACE6Q35872395-24AAD5FF-63AC-402F-86EC-32F2D7446F18Q35882896-F20EAC08-2AA0-4D1C-A491-CAC00CACD58CQ36109276-8C121B20-DE5D-4F86-958D-11F54A4C82E8Q36179320-F4D53266-FD2F-4349-AF4C-5281C567F4C7Q36180809-56DD3B31-71DC-4A98-A430-267C41EABC25Q36386806-8FDB7C77-0CC9-49B7-8565-49D0ECE880EFQ36534104-7B73C3FD-AAFB-4822-A542-E380FF50320EQ36554223-B12B212D-F649-49C5-AD2D-816F15DD48FAQ36611206-2A6BE4B7-4E38-44E6-9809-D0248A817ED0Q36673503-E79736BB-D809-47F0-ACE4-69F2D41810D2Q36787819-5FFF6987-1117-40AC-8347-409BE0ECC73BQ36902291-D50D5E25-E38A-4946-AA86-04971D5C23B4Q36959418-8A94EBDA-3506-4CDD-99C4-4AB24F0E36FBQ37020927-D10D4802-0852-456F-B872-B0C1BF1D5EC5Q37050743-0462E31E-F033-4059-BF7A-AEA3517880F4Q37112617-2A8EC89A-62B6-4250-A702-45746778F341Q37137830-D45E714D-31CE-4A0D-84D2-CE86B05C5AE5Q37156124-435FCEBD-8FB7-4739-A8E5-E7B7A94DB2D6Q37241902-B3169A3F-5098-42FA-A89C-FD64C7598302Q37326870-411471E4-FEB9-4C1A-8B8B-DBA440C4390F
P2860
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term consequences of the ...... erapy and regimen modification
@en
Long-term consequences of the ...... rapy and regimen modification.
@nl
type
label
Long-term consequences of the ...... erapy and regimen modification
@en
Long-term consequences of the ...... rapy and regimen modification.
@nl
prefLabel
Long-term consequences of the ...... erapy and regimen modification
@en
Long-term consequences of the ...... rapy and regimen modification.
@nl
P2093
P2860
P50
P1433
P1476
Long-term consequences of the ...... erapy and regimen modification
@en
P2093
Mark J van der Laan
Maya L Petersen
Richard D Moore
P2860
P304
P356
10.1097/QAD.0B013E32830F97E2
P407
P577
2008-10-01T00:00:00Z